Primary and Other Outcomes: DREAM

1
Primary and Other Outcomes DREAM
Data are number (). Rows are not mutually
exclusive for components of the compositeif a
participant had more than one component of the
composite then they are counted in the relevant
row. Regression implies achieving a normal
fasting glucose concentration (as defined in both
rows) and 2-h plasma glucose level. FPG fasting
plasma glucose. OGTT oral glucose tolerance
test.
DREAM investigators. Lancet 20063681096-1105.
2
Primary and Other Outcomes DREAM (contd)
Data are number (). Rows are not mutually
exclusive for components of the compositeif a
participant had more than one component of the
composite then they are counted in the relevant
row. Regression implies achieving a normal
fasting glucose concentration (as defined in both
rows) and 2-h plasma glucose level. Defined as
acute treatment with at least two of the
following criteria typical signs and symptoms,
typical radiological evidence, use of diuretics,
vasodilators, or inotropes.
DREAM investigators. Lancet 20063681096-1105.
3
Adverse Events, Hospitalization, and Death ADOPT
Plt0.05 for the comparison between this
treatment group and the rosiglitazone group
Plt0.01 for the comparison between this treatment
group and the rosiglitazone group.
ADOPT study group. N Engl J Med
20063552427-2443.
4
Laboratory Assessment and Concomitant Use of
Cardiovascular Drugs ADOPT
All laboratory values are mean values at 4
years Plt0.05 for the comparison between this
treatment group and the rosiglitazone group
Plt0.01 for the comparison between this treatment
group and the rosiglitazone group.
ADOPT study group. N Engl J Med
20063552427-2443.
5
Rates of Myocardial Infarction and Death from
Cardiovascular Causes
Nissen and Wolski. N Engl J Med
20073562457-2471.